Stadt Wien Wiener Gesundheitsverbund

At Stadt Wien Wiener Gesundheitsverbund, clinical trials in cardiovascular diseases focus on improving care for people at high risk of heart attack and stroke, as well as those living with heart failure and kidney impairment. These studies are designed to assess whether new treatments can better reduce serious cardiovascular events and support long-term heart health.

• Testing therapies to lower the risk of cardiovascular death, myocardial infarction, and ischemic stroke
• Evaluating treatment options for heart failure in patients with impaired kidney function
• Studying preventive strategies for adults with elevated cardiovascular risk

Research in this area aims to improve both prevention and treatment, with a strong emphasis on reducing major complications in everyday cardiac care.

The site’s Oncology and Hematology Department is actively involved in trials for several cancers and blood disorders, including multiple myeloma, chronic lymphocytic leukemia, urothelial carcinoma, renal cell carcinoma, and prostate cancer. These studies are exploring new treatment combinations and comparing them with current standard therapies to improve survival and disease control.

• Evaluating new approaches for relapsed or refractory multiple myeloma
• Comparing therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma
• Studying treatment strategies for advanced urothelial carcinoma and metastatic castrate-resistant prostate cancer
• Assessing novel options for advanced renal cell carcinoma

These trials are centered on finding more effective and better-tolerated therapies for difficult-to-treat malignancies.

Clinical research in immune system diseases at this hospital includes studies in rheumatoid arthritis, where investigators are comparing newer treatment approaches with established options. The goal is to better control inflammation, improve symptoms, and help patients maintain daily function.

• Comparing therapies for rheumatoid arthritis
• Assessing how newer immune-targeted treatments may improve disease management
• Exploring safer and more effective options for chronic inflammatory disease

This area reflects a broader effort to refine treatment choices for long-term autoimmune conditions.

The site also contributes to research in nervous system diseases, including Parkinson’s disease. These trials are aimed at evaluating whether investigational therapies can better manage symptoms or slow disease progression compared with placebo or current care.

• Studying potential therapies for Parkinson’s disease
• Assessing symptom control and disease-modifying potential
• Supporting development of improved options for neurodegenerative care

Work in this field is focused on advancing treatment possibilities for patients facing progressive neurological illness.

Trials in nutritional and metabolic diseases at Stadt Wien Wiener Gesundheitsverbund include studies that examine how lipid-lowering and other preventive therapies may reduce future complications in people with high cardiovascular risk. This research supports better management of underlying metabolic risk factors that contribute to serious disease.

• Evaluating therapies for people with elevated cardiovascular risk
• Studying prevention-focused approaches to reduce major vascular events
• Improving long-term management of metabolic and related cardiovascular conditions

These studies aim to strengthen prevention strategies and help lower the burden of chronic disease.